PLAY PODCASTS
Answering the Questions on Switching ART With Virologic Suppression
Episode 201

Answering the Questions on Switching ART With Virologic Suppression

Hear from expert faculty as they answer questions and discuss key considerations when determining whether and how to switch antiretroviral therapy in virologically suppressed individuals with HIV.

Decera Clinical Education Infectious Disease Podcast · Tristan J. Barber MA MD FRCP, Darcy Wooten MD

October 19, 202257m 26s

Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.

Show Notes

In this episode, Tristan J. Barber, MA, MD, FRCP, and Darcy Wooten, MD, discuss switching ART with virologic suppression, including:

  • Switching with prior or unknown resistance
    • Data on switching to BIC/FTC/TAF with a preexisting M184V/I mutation from a pooled analysis of 6 phase III studies
    • The impact of baseline resistance on outcomes following a switch to BIC/FTC/TAF in Black PWH from the BRAAVE 2020 study
    • A post hoc analysis of the SALSA study of DTG/3TC outcomes at Week 48 by baseline resistance
    • Data from the SOLAR 3D study on switching to DTG/3TC from a 3- or 4-drug ART regimen with a history of M184V
    • A retrospective analysis of switching to DTG/3TC with archived M184V/I from the French Dat’AIDS Cohort
  • Switching to long-acting ART
    • Guidance on candidates for LA CAB + RPV
    • Data on risk factors for virologic failure with LA CAB + RPV
  • Considering an ART switch after weight gain
    • Data on weight gain after ART initiation by ARV class and drug
    • Mean change in weight by sex at Week 96 in the ADVANCE study
    • DHHS guideline recommendations regarding weight gain with ART

Tristan J. Barber, MA, MD, FRCP
Honorary Associate Professor
Institute for Global Health
University College London
Consultant in HIV Medicine
Ian Charleson Day Centre
Royal Free Hospital
London, United Kingdom  

Darcy Wooten, MD
Associate Professor of Medicine
Division of Infectious Diseases and Global Public Health
Department of Medicine
University of California, San Diego
San Diego, California


Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Topics

dolutegravirnucleoside reverse transcriptase inhibitorlifestyle modificationscabotegravirpisbiccablong-acting artprotease inhibitorsbraave 2020agingbaseline resistancesuppressionnnrtisnon-nucleoside reverse transcriptase inhibitordtgsimplificationcvd risklaprior resistancefrench dat’aids cohortcab/rpvla artdhhs guidelinescab + rpvbic/ftc/taflamivudinetenofovir alafenamidebl resistance3tcrpvsolar 3dbictegravirantiretroviral therapyftcintegrase inhibitorspregnancyweight gainrisk factorspreexisting m184vmetabolic complicationsinstissalsaemtricitabineadvanceresistancenrtislong-actinghbvdrug-drug interactionsvirologically suppressedswitchdtg/3tctaftoxicityartrilpivirinehivcost